Fengming Y. Ran

Kunming, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features.

Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features.

Journal: Breast cancer research : BCR

Published: December 08, 2025

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Journal: The Lancet regional health. Western Pacific

Published: October 30, 2025

Malignant Melanoma Bone Metastasis With Unknown Primary Site: A Case Report and Literature Review.

Malignant Melanoma Bone Metastasis With Unknown Primary Site: A Case Report and Literature Review.

Journal: Case reports in orthopedics

Published: September 01, 2025

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Journal: Frontiers in pharmacology

Published: August 15, 2025

A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation.

A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with BRAF V600E mutation.

Journal: Frontiers in medicine

Published: July 11, 2025

Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.

Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: June 29, 2025

Psychological and physical distress in patients with advanced cancer after the COVID-19 pandemic: a cross-sectional study.

Psychological and physical distress in patients with advanced cancer after the COVID-19 pandemic: a cross-sectional study.

Journal: Scientific reports

Published: June 04, 2025

DNMT1-mediated LAMA2 inhibition induces M2 macrophage polarization during prostate cancer progression.

DNMT1-mediated LAMA2 inhibition induces M2 macrophage polarization during prostate cancer progression.

Journal: Tissue & cell

Published: May 28, 2025

GDF15 activates the PI3K/AKT pathway to mediate macrophage M2 polarization to promote prostate cancer resistance to docetaxel.

GDF15 activates the PI3K/AKT pathway to mediate macrophage M2 polarization to promote prostate cancer resistance to docetaxel.

Journal: Molecular immunology

Published: April 25, 2025

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies.

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies.

Journal: Cancer immunology, immunotherapy : CII

Published: December 02, 2024

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review.

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review.

Journal: Frontiers in oncology

Published: November 10, 2024

CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1.

CircBIRC6 affects prostate cancer progression by regulating miR-574-5p and DNAJB1.

Journal: Cancer biology & therapy

Published: September 11, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026